Table 4.
Multivariable-adjusted analysis for the association of demographic and clinical characteristics with all-cause mortality among 1477 Medicaid-insured women with preexisting type 2 diabetes mellitus diagnosed with breast cancer in New York State, 2004–2016.
| Variables | HR (95 % CI) a |
|---|---|
| Race/Ethnicity | |
| Non-Hispanic White | Referent |
| Non-Hispanic Black | 1.00 (0.76, 1.33) |
| Non-Hispanic Asian/Pacific Islander | 0.45 (0.27, 0.74) |
| Non-Hispanic Other | 0.38 (0.05, 2.76) |
| Hispanic | 0.74 (0.55, 0.99) |
| Estimated Menopausal Status b | |
| Premenopausal | Referent |
| Postmenopausal | 1.60 (1.02, 2.50) |
| Obese | |
| No | Referent |
| Yes | 0.65 (0.52, 0.83) |
| SEER Summary Staging | |
| Localized | Referent |
| Regional | 1.93 (1.48, 2.53) |
| Distant | 8.65 (5.72, 13.07) |
| Molecular Subtype | |
| HR+/HER2− | Referent |
| HR+/HER2+ | 1.27 (0.76, 2.13) |
| HRȒ/HER2+ | 0.99 (0.46, 2.13) |
| Triple-negative | 1.76 (1.11, 2.80) |
Abbreviations: HR, Hazard Ratio; 95 % CI, 95 % confidence interval; HR+, Estrogen receptor or progesterone receptor positive; HER2, human epidermal growth factor receptor 2.
Adjusted for race/ethnicity, estimated menopausal status, age at breast cancer diagnosis, breast cancer date of diagnosis, marital status at diagnosis, obesity, coronary heart disease, stroke, chronic kidney disease, molecular subtype, chemotherapy, surgery, hormone therapy, SEER Summary Staging, days between first type 2 diabetes mellitus diagnosis claim and breast cancer date of diagnosis.
Estimated menopausal status defined as: Premenopausal < 50 years of age and Postmenopausal ≥50 years of age.